drugset / Trial / NCT00929968

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

NCT00929968

Phase 2 Completed 35 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindPrevention

Summary

This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis

Timeline

Start
2009-06
Primary completion
2011-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone Other / unclassified
Subject VAK694 Unknown Intravenous

Indications